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Abstract
Aims: Constipation associated with opioid therapy for chronic pain may negatively
impact colonoscopy success. This retrospective, observational study using administra-
tive data and electronic medical records evaluated the impact of opioid use on colo-
noscopy outcomes.
Methods and Results: Procedural codes were used to identify patients who had a
screening colonoscopy at two Henry Ford Health System centers (January 2015–
December 2016). All patients had completed a standard uniform bowel preparation
protocol. Medication orders and filled prescriptions were used to identify patients with
a history of opioid use during the 28 days preprocedure (exposed) and a matched ran-
dom sample of presumptive opioid nonusers (unexposed). Electronic medical records
were reviewed for colonoscopy procedure data and outcomes.
The exposed and unexposed groups included 964 and 1054 patients, respectively.
Inadequate bowel preparation was significantly more common in the exposed versus
unexposed group (18.5% vs 12.7%; P < 0.001). In the exposed and unexposed
groups, 97.1 and 98.0% of colonoscopy procedures were completed, respectively
(P = nonsignificant). Total procedure time was slightly increased for the exposed ver-
sus unexposed group (23.8 vs 22.5 min; P = 0.039). Polyp identification and cancer
diagnosis were similar between groups. Prolonged sedation occurred in three patients
in the exposed group and none in the unexposed group. Procedural complications
were rare, but the incidence was significantly greater in the exposed versus unexposed
group (1.3% vs 0.2%; P < 0.01).
Conclusions: Opioid exposure was associated with significant reductions in the qual-
ity of preprocedure bowel preparation and an increased risk of complications in
patients undergoing colonoscopy.
Introduction
Colonoscopy is recommended in current guidance from the US
Multi-Society Task Force on Colorectal Cancer as a first-tier
screening test for colorectal cancer (CRC)1 and is the most com-
monly used test to screen for CRC.2 In 2012, approximately 6.5
million screening colonoscopies were performed in the United
States.2 The use of screening colonoscopies is associated with an
estimated 87% median reduction in the lifetime risk of CRC-
related death.3 Based on improvements in CRC outcomes with
screening colonoscopies, the National Colorectal Cancer Round-
table initiative has proposed a goal of increasing the CRC screen-
ing rate among adults 50 years of age and older to 80% in the
United States.4
A reduction in the risk of advanced and fatal CRC using
screening colonoscopies depends on the detection of adenomas,5
and the diagnostic accuracy and safety of colonoscopy for
detecting colonic lesions depend, in part, on the quality of bowel
preparation.6,7 Bowel preparation has been shown to be
suboptimal in approximately 10–35% of colonoscopies,8,9 and
suboptimal bowel preparation may, in part, be due to the pres-
ence of chronic constipation and use of medications that slow
gut motility.10 Inadequate bowel preparation has been associated
with a 44% decrease in the chance of detecting early colonic
polyps and a 23% decrease in the chance of detecting advanced
polyps.6 Along with contributing to missed adenomas, inade-
quate bowel preparation may be associated with an increased risk
of procedure-related complications,11 as well as increased costs,
increased procedure times, canceled procedures, and the need for
repeat examination.12
Chronic pain is one of the most common reasons for
seeking medical care in the United States, and it is estimated
that up to 20% of patients with noncancer chronic pain are pre-
scribed opioid analgesics in the outpatient setting.13–15 Consti-
pation has been reported in approximately 40–80% of patients
taking opioids for chronic pain.16,17 Several large studies have
shown that prior exposure to opioids (at both low and high
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doses) represents an independent risk factor for poor bowel
preparation.8,18
The current study was conducted to evaluate not only the
quality of bowel preparation for patients on opioid therapy but
also the impact of opioid use on colonoscopy outcomes.
Methods
Study design. This retrospective, observational study used
administrative and electronic medical record (EMR) data from
patients undergoing colonoscopy at two medical centers in the
Henry Ford Health System (HFHS). Colonoscopy procedures,
performed by practicing physicians or fellows in training, were
limited to these two sites to minimize variability in provider
behavior and provider documentation practices. The majority
(90%) of patients undergoing colonoscopy in the HFHS receive
a standard split bowel preparation (polyethylene glycol 3350 and
electrolytes oral solution [Braintree Laboratories, Inc. Braintree,
MA, USA] or sodium sulfate, potassium sulfate, and magnesium
sulfate oral solution [Braintree Laboratories, Inc.]). Patients who
had a previous poor bowel preparation or are believed by the cli-
nician to be at high risk for a poor bowel preparation receive an
extended, two-day preparation. No alterations in the bowel prepa-
ration procedure are made for patients taking opioids. Colonosco-
pies were performed using standard procedures at the two
medical centers, using either air or carbon dioxide for insuffla-
tion. This study was approved by the HFHS Institutional Review
Board on November 6, 2016.
Patient selection. Screening colonoscopies in adults
(≥18 years of age) performed in 2015 and 2016 were identified
using Current Procedural Terminology, 4th edition (CPT-4;
American Medical Association) codes. Patients with diagnostic
and treatment-related colonoscopy codes were not included in
order to minimize clinical factors that might influence the colo-
noscopy procedure. The codes included were: 45380 (colonos-
copy, flexible, with biopsy single or multiple), 45385
(colonoscopy, flexible proximal to splenic flexure, with removal
of tumor), G0105 (CRC screening colonoscopy on individual at
high risk), and G01021 (colorectal screen colonoscopy on indi-
vidual not meeting high-risk criteria). In the event that a patient
had two colonoscopies during the study time frame, the first pro-
cedure was used as the study colonoscopy.
Assessment of opioid exposure. Medication orders and
prescriptions filled during a period of six months prior to the
colonoscopy date were reviewed for assessment of opioid expo-
sure. Patients who had documented opioid use within the 28 days
prior to the colonoscopy date were classified as presumptive opi-
oid users (exposed group). In identifying the presumptive
exposed group, patients with a medication order or filled pre-
scription for an opioid 42 days prior to the date of colonoscopy
were included for subsequent EMR review to confirm the opioid
exposure window based on the assumption that an order or pre-
scription for an opioid for chronic pain would be for at least a
two-week supply of medication. Patients with an opioid order
only on the date of the colonoscopy were not considered part of
the exposed group due to the use of opioids for sedation during
the procedure. In addition, patients with historical exposure to
opioids (i.e. with evidence of exposure >42–180 days prior to the
procedure) but no recent (within 42 days of the procedure) evi-
dence of opioid exposure were excluded from the study. The
remaining patients were presumed unexposed to opioid medica-
tion. Additional exclusion criteria were a documented history of
CRC or exposure to the mixed opioid agonist–antagonists
buprenorphine, butorphanol, or nalbuphine within 180 days
preprocedure.
A total of 15 561 colonoscopy records were retrieved from
the EMRs. After excluding patients based on prespecified
criteria, as shown in Figure 1, a final analysis population was
determined, which included 964 patients exposed to opioids and
1054 patients unexposed to opioids.
Data abstraction. Study data were collected and managed
using Research Electronic Data Capture (REDCap) electronic
data capture tools hosted at HFHS.19 REDCap is a secure, web-
based application designed to support data capture for research
studies, providing: (i) an intuitive interface for validated data
entry, (ii) audit trails for tracking data manipulation and export
procedures, (iii) automated export procedures for seamless data
downloads to common statistical packages, and (iv) procedures
for importing data from external sources. The electronic medical
record, Epic (Copyright 2018 Epic Systems Corporation) was
reviewed to abstract opioid exposure, opioid use (specific drug,
indication, formulation, dosage, duration of exposure), and data
on colonoscopy procedures and outcome variables.
Quality checks. Two quality assurance studies were con-
ducted to assess the accuracy of data abstraction, in addition to
two pilot studies, prior to finalizing the study variables and data-
base containing the study population. The quality assurance stud-
ies involved selection of a random sample of 5% of abstracted
cases, which were subjected to review by a second abstractor,
and the results were compared.
Outcome measures. The primary objective of this study
was to compare the incidence of failed or inadequate colonos-
copy in patients exposed to opioids with those unexposed to opi-
oids. Secondary objectives included comparing the quality of
bowel preparation (recorded in the procedure report at the time
of the colonoscopy by the physician), intraprocedural time, inci-
dence of repeat (rescheduled) colonoscopy, complications of
colonoscopy, and the proportion of patients with abnormal find-
ings (polyps, etc.) in the presumed exposed and unexposed
groups.
Bowel preparation data were collected during the colonos-
copy procedure and recorded by the endoscopist as excellent,
good, fair, or poor and subsequently dichotomized into adequate
(excellent and good) versus inadequate (fair and poor) for analy-
sis. Generally, the criteria for adequacy of bowel preparation
included the ability to visualize the colonic mucosa and to
achieve cecal intubation. Other information retrieved from the
EMRs included the time to cecum, total procedural time, compli-
cations, recommendation and date of any repeat colonoscopy,
and findings (for study and repeat colonoscopies: lesions, tissue
sampling, pathology reports). Procedure-related complications
were defined as lack of completion, prolonged sedation, bleed-
ing, perforation, or other complications. Colonoscopy completion
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was assessed as a separate outcome. Incidents that were consid-
ered unrelated to the colonoscopy were not included in this
assessment. Unplanned hospitalization following colonoscopy
was also captured.
Statistical analyses. Demographic characteristics of the
opioid-exposed and -unexposed groups were compared using
chi-squared test or Fisher’s exact test. As noted previously,
bowel preparation was dichotomized into adequate (excellent or
good) and inadequate (fair or poor) categories. These were intro-
duced into a binary logistic regression model that included
gender, ethnicity, age category, and opioid exposure. Unadjusted
and adjusted odds ratios (ORs) were then calculated, together
with P values.
Results
Patients. When comparing the opioid-exposed and -unexposed
groups, mean age was comparable, and there were no differences
in gender distribution (Table 1). However, significant differences
were observed between age categories for the exposed and
unexposed groups, with a higher proportion of patients in the
Figure 1 Final population. CRC, colorectal cancer; GI, gastrointestional. †21 patients were reclassified as opioid unexposed based on chart review.
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exposed group in the youngest subset (18–49 years of age). In
addition, the proportion of Asians was higher in the unexposed
group than in the exposed group.
Approximately one-quarter of the exposed patients used
opioids for less than one week, whereas 61% used opioids for at
least 28 days. A total of 39% of exposed patients had used opi-
oids for more than four months. When opioid exposure was eval-
uated by demographic characteristics, a higher proportion of
patients in the youngest age category (18–49 years of age) used
opioids for less than one week to 27 days compared with the
other age categories (P < 0.001). In addition, a higher proportion
of women used opioids for at least 28 days (P < 0.05). The most
commonly used opioids included hydrocodone/hydrocodone +
acetaminophen (46.8% of exposed patients), morphine/morphine
sulfate (25.7%), tramadol (20.2%), and fentanyl (19.5%). During
the four-week period prior to colonoscopy, 58% of patients
exposed to opioids received one opioid, 28% received two opi-
oids, and 14% received three or more opioids. The most common
indications for opioid use were abdominal pain (25%), back pain
(22%), and arthritis or joint pain (20%).
Colonoscopy characteristics and outcomes. There
was a significant difference between the opioid-exposed and
-unexposed groups for the quality of bowel preparation, with
lower proportions of opioid-exposed patients than unexposed
patients having excellent (0.8% vs 2.4%) or good (80.7% vs
84.9%) preparations (Fig. 2). Bowel preparation was considered
adequate (excellent or good) in 81.5% of patients exposed to opi-
oids compared with 87.3% of patients unexposed to opioids
(P < 0.001; Fig. 2). The rate of completed colonoscopies was
high (>97%) in both groups, and time to cecum was similar. The
overall procedure time (excluding patients for whom the proce-
dure was unable to be completed) was slightly increased for
patients in the opioid-exposed group compared with the
unexposed group (mean, 23.9 vs 22.6 min; P = 0.039; Table 2);
Table 1 Baseline characteristics for patients exposed to opioids and
patients unexposed to opioids†
Characteristic n Exposed Unexposed P value
Gender
Male 884 414 (46.8) 470 (53.2) 0.457
Female 1134 550 (48.5) 584 (51.5)
Age, years, mean 58.0 59.1 0.065
Age category, years <0.001
18–49 307 179 (58.3) 128 (41.7)
50–59 705 311 (44.1) 394 (55.9)
60–69 693 309 (47.0) 384 (53.0)
≥70 349 165 (47.3) 184 (52.7)
Race <0.001
White 741 352 (47.5) 389 (52.5)
African American 995 506 (50.9) 489 (49.1)
Hispanic 62 29 (46.8) 33 (53.2)
Asian 35 8 (22.9) 27 (77.1)
Other/unknown 185 69 (37.3) 116 (62.7)
†Values are n (%) unless otherwise specified.
Figure 2 Adequacy of bowel preparation for patients exposed to opi-
oids and patients unexposed to opioids. †Exposed versus unexposed
for bowel preparation quality (excellent, good, fair, poor) and adequacy
(adequate, inadequate).
Table 2 Summary of colonoscopy procedures and outcomes for
patients exposed to opioids and patients unexposed to opioids†
Exposed
(n = 964)
Unexposed
(n = 1054) P value
Colonoscopy completed 936 (97.1) 1033 (98.0) 0.184
Time to cecum, min, mean 7.9 7.5 0.149
Missing data 98 (10.1) 108 (10.2)
Colonoscopy procedure time, min,
mean
23.9 22.6
Missing data 175 (18.1) 178 (16.9) 0.039
Polyps identified, patients 518 (53.7) 580 (55.0) 0.589
Number of polyps removed, mean 2.3 2.5 0.162
Cancer diagnosis‡ 11 (1.1) 6 (0.6) 0.160
Repeat colonoscopy recommended 63 (6.5) 67 (6.4) 0.866
Reason for repeat colonoscopy
Inadequate bowel preparation 40 (53.3) 35 (46.7) 0.194
Other 23 (41.8) 32 (58.2)
Repeat colonoscopy completed
within 6 months
42 (66.7) 47 (70.1) 0.669
Prolonged sedation 3 (0.3) 0 (0) 0.109
All complications (patients) 15 (1.6) 3 (0.3) <0.01
Procedure-related complications 13 (1.3) 2 (0.2) <0.01
Type of procedure-related
complication§
Abdominal pain 8 (0.8) 2 (0.2) 0.055
Bleeding 4 (0.4) 0 (0) 0.052
Perforation 1 (0.1) 0 (0) 0.487
Other 5 (0.5) 2 (0.2) 0.269
Unplanned hospitalization following
colonoscopy
4 (0.4) 1 (0.1) 0.199
†Values presented are n (%), unless otherwise specified.
‡Colorectal cancers with the exception of one case of metastatic pros-
tate cancer.
§Patients may have experienced more than one type of procedure-related
complication.
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however, it should be noted that the time was not documented in
18 and 17% of EMRs, respectively.
There were no differences between groups for the rate of
polyp detection or polyp removal (Table 2). Of the 1908 patients
who had a polyp identified, 1078 had tissue removed, which was
determined as adenomatous in 726 cases. A diagnosis of CRC
was made in 16 patients and metastatic prostate cancer in
one patient. The need for repeat colonoscopy was similar in the
opioid-exposed and -unexposed groups (6.5% vs 6.3%). Inade-
quate bowel preparation was the reason for repeat colonoscopy
in 75 patients (exposed group, n = 40; unexposed group, n = 35;
P = 0.194).
The rate of procedural complications was low in both
groups but was significantly more frequent in patients with
prior opioid exposure compared with patients unexposed to
opioids (1.3% vs 0.2%; P < 0.01; Table 2). Complications in
three patients were unrelated to the procedure; these included
an incident of ulcerative colitis (previously diagnosed) requiring
intravenous steroids (exposed group), bradycardia during the pro-
cedure (unexposed group), and an anesthesia-related complication
(exposed group). Rates of unplanned hospitalization following
colonoscopy were low in both groups.
Irrespective of whether patients had adequate or inadequate
bowel preparation, there were no differences in the requirement
for repeat colonoscopy, prolonged sedation, and unplanned hospi-
talizations following colonoscopy between the opioid-exposed
and opioid-unexposed groups (Table 3). In the subset of patients
who had an adequate bowel preparation, patients who were
exposed to opioids had a higher frequency of procedure-related
complications and bleeding than those who were unexposed to
opioids. The few patients who reported complications of bleeding
or perforation had no complications noted during the procedure.
All patients with bleeding or perforation complications had polyps
removed and subsequently presented to the emergency room with
postprocedure symptoms of hematochezia or hematemesis. No
invasive interventions or transfusions were required. In the subset
of patients with inadequate bowel preparation, there were no sig-
nificant differences in complications between patients exposed to
opioids and those unexposed to opioids. In this subset, inadequate
bowel preparation necessitated repeat colonoscopy in 89.7% of
patients in the opioid-exposed group and 86.5% of patients in the
unexposed group.
From the binary logistic regression model, it was found
that exposure to opioids and male gender were both indepen-
dently associated with a significantly reduced likelihood of ade-
quate bowel preparation (Table 4). No influence of ethnicity or
age category was noted.
Table 3 Summary of colonoscopy procedures and outcomes for
patients exposed to opioids and patients unexposed to opioids†
Procedure and outcomes Exposed Unexposed P value
Adequate bowel preparation n = 786 n = 920
Repeat colonoscopy recommended 24 (3.1) 30 (3.3) 0.811
Reason for repeat colonoscopy 0.443
Inadequate bowel preparation 5 (20.8) 2 (10.0)
Other 19 (79.2) 27 (90.0)
Prolonged sedation 2 (0.3) 0 (0) 0.212
Procedure-related complications 8 (1.0) 1 (0.1) <0.01
Type of procedure-related
complication‡
Abdominal pain 4 (0.5) 1 (0.1) 0.187
Bleeding 4 (0.5) 0 (0) <0.05
Perforation 0 (0) 0 (0) NA
Other 3 (0.4) 1 (0.1) 0.340
Unplanned hospitalization following
colonoscopy
2 (0.3) 1 (0.1) 0.560
Inadequate bowel preparation n = 178 n = 134
Repeat colonoscopy recommended 39 (21.9) 37 (27.6) 0.245
Reason for repeat colonoscopy 0.733
Inadequate bowel preparation 35 (89.7) 32 (86.5)
Other 4 (10.3) 5 (13.5)
Prolonged sedation 1 (0.6) 0 (0) 0.999
Procedure-related complications 5 (2.8) 1 (0.7) 0.242
Type of procedure-related
complication‡
Abdominal pain 4 (2.2) 1 (0.7) 0.396
Bleeding 0 (0) 0 (0) NA
Perforation 1 (0.6) 0 (0) 0.999
Other 2 (1.1) 1 (0.7) 0.999
Unplanned hospitalization following
colonoscopy
2 (1.1) 0 (0) 0.508
NA, not applicable.
†Values presented are n (%).
‡Patients may have experienced more than one type of procedure-related
complication.
Table 4 Logistic regression for adequacy of bowel preparation
Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Opioid exposed versus unexposed 0.64 (0.50–0.82) <0.01 0.64 (0.50–0.81) <0.001
Male versus female 0.70 (0.55–0.89) <0.01 0.69 (0.54–0.88) <0.01
Ethnicity
White (reference) 1.00
African American 0.88 (0.67–1.14) 0.33
Hispanic 0.79 (0.40–1.57) 0.50
Asian 2.81 (0.67–11.88) 0.16
Other/unknown 0.92 (0.59–1.43) 0.71
Age category† 1.05 (0.92–1.19) 0.47
CI, confidence interval; OR, odds ratio.
†Age categories: 18–49 years, 50–59 years, 60–69 years, and ≥ 70 years.
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Discussion
The aim of the current study was to compare colonoscopy out-
comes between patients who were opioid users within a rela-
tively close time frame to the colonoscopy procedure and
those who had not been exposed to opioids; thus, patients with
evidence of current opioid exposure within the month prior to
the procedure were selected for inclusion in the analysis, while
those with only historical exposure were excluded. These
selection criteria for opioid exposure were considered sufficient
to have an impact on gastrointestinal motility, while the
criteria for unexposed patients likely provided sufficient time
since the termination of opioid use to allow for complete
washout of the opioid effect on motility and any corresponding
effect on bowel preparation. Based on these criteria, 7.4% of
patients who had undergone screening colonoscopy were
included in the opioid-exposed group. This rate was compara-
ble to that in a previous retrospective study of outpatients
undergoing colonoscopy, in which 8.6% were identified as reg-
ular opioid users.18
Although there was no significant difference in the propor-
tion of completed colonoscopies for patients in the opioid-
exposed and opioid-unexposed groups, opioid exposure was
associated with a significantly lower proportion of patients with
adequate bowel preparation compared with the opioid-unexposed
group. Male gender was also independently associated with
poorer bowel preparation quality prior to screening colonoscopy.
Findings from previous studies support the association of opioid
exposure and male gender with poor bowel preparation qual-
ity.8,18,20 In addition, the proportion of patients who were
unexposed to opioids with adequate bowel preparation was com-
parable in this study (87.3%) with that reported in previous stud-
ies (75.6% and 90.7%).8,18 In the current study, the use of
opioids was also shown to have an impact on other colonoscopy
outcomes, beyond the adequacy of bowel preparation. The time
to cecum was comparable regardless of opioid exposure; how-
ever, those patients exposed to opioids had a slightly longer
overall procedure time, but this difference was not clinically sig-
nificant. It has been suggested that patients with a history of opi-
oid use are more difficult to sedate,21 which could potentially
contribute to this observed difference in procedure time. Further-
more, although the rate of procedure-related complications was
low in both groups, procedural complications were observed in a
significantly higher proportion of patients exposed to opioids
compared with unexposed patients.
In this study, only a small proportion of patients (approxi-
mately 6.5%) required repeat colonoscopy, which was necessi-
tated by inadequate bowel preparation in approximately 50% of
cases for both patients exposed and unexposed to opioids. When
comparing adequate and inadequate bowel preparation, there
were no differences in the need for repeat procedures according
to opioid exposure.
CRC is the third leading cause of cancer-related death in
the United States22; however, early diagnosis allows for identifica-
tion of early-stage, localized disease, which has a 5-year survival
rate of 90%.23 Colonoscopy is the current standard for screening
for CRC,1 and more than 6 million screening colonoscopies are
performed in the United States in a single year.2 Adequate bowel
preparation is essential for colonoscopy success.6,7,11 The pres-
ence of chronic constipation may have a negative impact on
bowel preparation,10 and the use of opioids for chronic noncancer
pain is often associated with constipation.16,17 To achieve the
current goal of increasing screening colonoscopies,4 colonoscopy
suite efficiency will need to be maximized, while the wasted
resources (e.g. endoscopy suite time; nurse, anesthesiologist, and
endoscopist time; medical supplies/equipment for colonoscopy)
associated with incomplete and repeated procedures will need to
be minimized. In the HFHS, repeat colonoscopy is also associated
with substantial additional costs, with total uninsured costs listed
as $1730 for a screening colonoscopy, $1850 for colonoscopy
with biopsy, and $1950 for colonoscopy with polyp removals.24
Maximizing colonoscopy suite efficiency will require identifying
patients with known risk factors for inadequate bowel preparation,
including opioid use, who may benefit from more aggressive
bowel preparation12 or from patient education regarding the
methods and benefits of adequate bowel preparation.25
The strengths of this study included the relatively large
sample size and high likelihood of consistent procedural
approach because data were restricted to two centers within
the same health system. There were also some potential limi-
tations. It is well established that patients with diabetes expe-
rience issues with bowel preparation20,26 and may require
specific preparation regimens.27 Use of other medications and
patients’ functional status may also affect bowel motility;
however, comorbidities (e.g. diabetes), other medications,
and patients’ functional status were not explored as potential
modifying factors in the current analysis. In addition,
although screening colonoscopies were selected during data
capture based on CPT-4 codes, potential coding irregularities
may have affected the data included. In addition, there were
fewer Asian patients and more patients in the youngest age
category in the opioid-exposed group; however, in the
regression analysis, neither ethnicity nor age category was
found to be associated with adequate bowel preparation.
This is in agreement with previous studies evaluating bowel
preparation.28
This study supports the results of previous studies8,18
showing the negative impact of opioid use on bowel preparation
but also indicates that opioid use may be associated with more
procedure-related complications and slightly longer procedure
times. These differences were generally relatively small. Never-
theless, these results suggest that additional measures to optimize
bowel preparation prior to colonoscopy may be necessary for
some patients taking opioids. Additional research is needed to
determine which methods of bowel preparation or other measures
(e.g. educational interventions) may be most beneficial for
chronic opioid users.
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